Pramipexole, the most commonly prescribed dopamine agonist worldwide, meanwhile serves as a reference substance for evaluation of new drugs. Based on numerous clinical data and vast experiences, efficacy and safety profiles of this non-ergoline dopamine agonist are well characterized. Since October 2009, an extended-release formulation of pramipexole has been available for symptomatic treatment...

OBJECTIVE The purpose of this study was to determine the efficacy and safety of a novel extended-release metformin in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Adults with type 2 diabetes (newly diagnosed, treated with diet and exercise only, or previously treated with oral diabetic medications) were randomly assigned to receive one of three extended-release metformin treatme...

OBJECTIVE A subgroup of patients with Tourette's disorder (TD) has symptoms refractory to haloperidol, a standard therapeutic drug for TD. METHODS We report on three cases of pediatric and adolescent patients who were treated with paliperidone extended release. RESULTS In two cases, TD symptoms were remarkably improved by switching from haloperidol to paliperidone extended release, and in a...

1 INDICATIONS AND USAGE Alfuzosin hydrochloride extended release tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. 1.1 Important Limitations of Use Alfuzosin hydrochloride extended release tablets are not indicated for the treatment of hypertension. Alfuzosin hydrochloride extended release tablets are not indicated for use in the pediatric population...

OBJECTIVE To compare the estimated first-line treatment costs of extended-release tolterodine versus controlled-release oxybutynin in patients with overactive bladder (OAB). METHODS We developed a decision-analysis model to estimate the patterns of treatment, resource consumption, and cost impact of treating OAB with either controlled-release oxybutynin or extended-release tolterodine as firs...

G lucagon-like peptide-1 (GLP-1) receptor agonists are safe and effective U.S. Food and Drug Administration (FDA)-approved drug products for use in the treatment of type 2 diabetes. To date, the FDA has approved five GLP-1 receptor agonist parenteral formulations: exenatide, liraglutide, exenatide extended-release , and, most recently, albiglutide and dulaglutide. All of these formulations are ...